發(fā)布時間：2018-08-05 14:17

【摘要】：正AOBiome公司完成其領(lǐng)先候選藥B244治療高血壓的Ⅱ期臨床試驗的患者入選工作。該試驗是隨機、雙盲、安慰劑對照研究,入選116名收縮期高血壓患者,主終點是4周治療后,給藥組與賦形劑對照,平均降低收縮期高血壓的初步效果和安全性。先前的Ⅰ/Ⅱa期臨床試驗顯示,B244治療尋常性痤瘡者無嚴(yán)重副作
[Abstract]:AOBiome was selected to complete a phase II clinical trial of its leading candidate drug B244 for the treatment of hypertension. The trial was a randomized, double-blind, placebo controlled trial. 116 patients with systolic hypertension were enrolled in the study. The primary effect and safety of systolic hypertension were reduced on average in the administration group and excipient group after 4 weeks of treatment. Previous stage 鈪，

本文編號：2166045